ZyVersa Therapeutics (ZVSA) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 11, 2025, to be held virtually, with voting on five key proposals including director elections, auditor ratification, equity plan amendment, and approval of warrant issuances.

• Company focuses on developing drugs for chronic renal and inflammatory diseases, with two proprietary platforms in clinical and preclinical stages.

• Forward-looking statements highlight ongoing clinical trials, planned IND submissions, and potential market expansion.

Voting matters and shareholder proposals

• Election of two Class III directors (Stephen C. Glover and Robert G. Finizio) for three-year terms.

• Ratification of CBIZ as independent registered public accounting firm for 2025.

• Amendment to 2022 Omnibus Equity Incentive Plan to increase reserved shares by 100,000 to 382,122.

• Approval of issuance of up to 1,637,000 shares upon exercise of warrants from November 2024 Warrant Inducement.

• Approval of issuance of up to 2,105,265 shares upon exercise of warrants from March 2025 PIPE.

Board of directors and corporate governance

• Board consists of five members, majority independent, with Stephen C. Glover as CEO and Chairman.

• Board committees include audit, compensation, and nominating/governance, each with written charters and independent membership.

• No family relationships among directors or executive officers.

• Board met four times in 2024; all members attended at least 75% of meetings.